Kynam Capital Management, LP Affimed N.V. Transaction History

Kynam Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $47,733 - $80,855	-24,354 Reduced 3.47%	676,675 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $801,455 - $1.72 Million	353,064 Added 101.47%	701,029 $1.94 Million
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $59,290 - $90,784	-16,068 Reduced 4.41%	347,965 $1.52 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $1.95 Million - $2.57 Million	364,033 New	364,033 $2.01 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.